OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA
2020.May.29
OBI has filed application of Phase I/II human clinical studies for passive immunotherapeutic monoclonal antibody OBI-888 to TFDA
2020.May.26
OBI has signed a non-binding MOU to form a strategic partnership to develop novel bispecific antibody cancer treatments
2020.May.08
Supplementary statement for 2020 Shareholders’ Meeting (Change in location and new items)
2020.Apr.11
The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by Ministry of Food and Drug Safety of South Korea to proceed Phase III human clinical study
2020.Apr.08
Due to the tense situation of Novel Coronavirus Disease (COVID-19), company decided to pause the recruitment of Global Phase III clinical study for 3 months and will restart recruitment when epidemic gets controlled.
2020.Mar.25
Updates on company’s negotiable securities for investors’ information
2020.Mar.13
Announcement on change of accountant due to internal adjustment of accounting firm
2020.Mar.13
The Board of Directors resolved to hold 2020 Annual General Meeting
2020.Mar.13
The board of directors have resolved not to distribute dividends for 2019
